ArticlePloS one2011
Molecular epidemiology and evolution of human respiratory syncytial virus and human metapneumovirus.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 58 citations in OpenAlex.
- Characterization of hospital and community-acquired respiratory syncytial virus in children with severe lower respiratory tract infections in Ho Chi Minh City, Vietnam, 2010.Influenza and other respiratory viruses · 2015Trial
- Avian Metapneumovirus: Virology, Epidemiology, and Insights from a Comparative Analysis with Human Metapneumovirus-A Review.Biomolecules · 2026Review
- Human Metapneumovirus-associated Hospital Burden in Older Adults in Scotland: A Retrospective Analysis.Open forum infectious diseases · 2026Article
- Genotype turnover and global evolutionary dynamics of G gene duplication variants in human metapneumovirus: insights from prospective surveillance in Nantong, China, 2024-2025.Frontiers in microbiology · 2026Article
- Metavac-RSV mucosal bivalent vaccine candidate protects cotton rats against pneumoviruses and is produced using serum-free cell culture in bioreactor.NPJ vaccines · 2025Article
- Immunoinformatic design of chimeric multiepitope vaccine for the prevention of human metapneumovirus (hMPV).BMC infectious diseases · 2025Article
- Immunological insights into the re-emergence of human metapneumovirus.Current opinion in immunology · 2025Review
- Insights from respiratory virus co-infections.World journal of virology · 2024Review
- Development of a novel multi-epitope mRNA vaccine candidate to combat HMPV virus.Human vaccines & immunotherapeutics · 2023Article
- Role of human metapneumovirus glycoprotein G in modulation of immune responses.Frontiers in immunology · 2022Article
- Detailed Evolutionary Analyses of the F Gene in the Respiratory Syncytial Virus Subgroup A.Viruses · 2021Article
- Evolution of respiratory syncytial virus genotype BA in Kilifi, Kenya, 15 years on.Scientific reports · 2020Article
- The Impact of RSV-Associated Respiratory Disease on Children in Asia.Journal of pediatric infectious diseases · 2019Review
- Sequence Analysis of the Fusion Protein Gene of Human Respiratory Syncytial Virus Circulating in China from 2003 to 2014.Scientific reports · 2018Article
- 180-Nucleotide Duplication in the G Gene ofFrontiers in microbiology · 2017Article
- Human metapneumovirus epidemiological and evolutionary patterns in Coastal Kenya, 2007-11.BMC infectious diseases · 2016Article
- Direct whole-genome deep-sequencing of human respiratory syncytial virus A and B from Vietnamese children identifies distinct patterns of inter- and intra-host evolution.The Journal of general virology · 2015Article
- Conservation of G-Protein Epitopes in Respiratory Syncytial Virus (Group A) Despite Broad Genetic Diversity: Is Antibody Selection Involved in Virus Evolution?Journal of virology · 2015Article
- Recent vaccine development for human metapneumovirus.The Journal of general virology · 2015Review
- Sequencing and analysis of globally obtained human respiratory syncytial virus A and B genomes.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
Abstract
Human respiratory syncytial virus (HRSV) and human metapneumovirus (HMPV) are ubiquitous respiratory pathogens of the Pneumovirinae subfamily of the Paramyxoviridae. Two major surface antigens are expressed by both viruses; the highly conserved fusion (F) protein, and the extremely diverse attachment (G) glycoprotein. Both viruses comprise two genetic groups, A and B. Circulation frequencies of the two genetic groups fluctuate for both viruses, giving rise to frequently observed switching of the predominantly circulating group. Nucleotide sequence data for the F and G gene regions of HRSV and HMPV variants from the UK, The Netherlands, Bangkok and data available from Genbank were used to identify clades of both viruses. Several contemporary circulating clades of HRSV and HMPV were identified by phylogenetic reconstructions. The molecular epidemiology and evolutionary dynamics of clades were modelled in parallel. Times of origin were determined and positively selected sites were identified. Sustained circulation of contemporary clades of both viruses for decades and their global dissemination demonstrated that switching of the predominant genetic group did not arise through the emergence of novel lineages each respiratory season, but through the fluctuating circulation frequencies of pre-existing lineages which undergo proliferative and eclipse phases. An abundance of sites were identified as positively selected within the G protein but not the F protein of both viruses. For HRSV, these were discordant with previously identified residues under selection, suggesting the virus can evade immune responses by generating diversity at multiple sites within linear epitopes. For both viruses, different sites were identified as positively selected between genetic groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.